News
Molecular Therapy | RinuaGene Publishes Early Research Data
May 16, 2024
RinuaGene Biotechnology Co., Ltd. has advanced its self-developed mRNA therapeutic vaccine RG002 for HPV-related tumors and precancerous lesions into clinical development.
A research paper on this early development work, titled "Development of an mRNA-based therapeutic vaccine mHTV-03E2 for high-risk HPV-related malignancies," has been published in the prestigious journal Molecular Therapy. RinuaGene and the Institute of Medical Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, are the joint corresponding institutions for this article.
A Joyous Start to 2024: RinuaGene Achieves Another Milestone
January 5, 2024
The Suzhou Science and Technology Bureau has announced the 2023 list of proposed "Unicorn Cultivation" enterprises. RinuaGene has been successfully included on this list due to its strength in technological innovation, high-quality growth, and development potential.
RinuaGene Selected as a 2023 "Potential Unicorn Enterprise" in Jiangsu
December 19, 2023
The Jiangsu Productivity Promotion Center has released the 2023 assessment results for Jiangsu's unicorn enterprises. RinuaGene Biotechnology Co., Ltd. has distinguished itself among numerous candidates and has been successfully named a "Potential Unicorn Enterprise" in Jiangsu.
RinuaGene's Project Chosen for 2023 National Center of Technology Innovation for Biopharmaceuticals
December 14, 2023
The 2023 National Center of Technology Innovation for Biopharmaceuticals' "Revealing the List and Taking the Lead" program has announced its proposed project list for technical breakthroughs in cell therapy. RinuaGene Biotechnology Co., Ltd.'s project, "Efficient and Specific Targeted mRNA-LNP Delivery System for Immune Cells," has been successfully selected as an innovative project.
RinuaGene's HPV-Related Therapeutic mRNA Vaccine Receives FDA IND Approval
November 6, 2023
RinuaGene Biotechnology Co., Ltd. has announced that its self-developed HPV-related therapeutic mRNA vaccine RG002 received FDA Investigational New Drug (IND) approval on October 27, 2023. This approval is for treating HPV type 16 and/or 18-related cervical intraepithelial neoplasia (CIN2/3), making it the world's first approved mRNA-LNP therapeutic vaccine for this indication. The company is also progressing with its clinical trial application to the National Medical Products Administration (NMPA).
© 2024 RinuaGene. All Rights Reserved.
This website uses cookies.
We use cookies to analyze website traffic and optimize your website experience. By accepting our use of cookies, your data will be aggregated with all other user data.